microRNA

microRNA Market Outlook

The global microRNA market is projected to reach USD 4.2 billion by 2035, growing at a CAGR of 12.7% during the forecast period 2025-2035. This growth is primarily driven by the increasing prevalence of chronic diseases, rising investments in research and development for innovative therapeutics, and the expanding applications of microRNAs in diagnostics. Additionally, the surge in the adoption of personalized medicine is expected to further bolster the market as microRNAs play a crucial role in gene regulation and expression. Furthermore, technological advancements and the increasing availability of diagnostic tools utilizing microRNA profiling are set to create lucrative opportunities for market expansion. This robust growth trajectory showcases the vital role of microRNAs in the present and future of clinical and therapeutic applications.

Growth Factor of the Market

Several factors are driving the growth of the microRNA market. The escalating incidence of various chronic diseases, including cancer and cardiovascular disorders, highlights the necessity for effective diagnostic and therapeutic solutions, thereby enhancing the demand for microRNA-based applications. Furthermore, the burgeoning field of molecular biology and genomics research has resulted in increased funding and investment from both private and public sectors, facilitating advancements in microRNA studies. Concomitantly, the growing awareness regarding personalized medicine and the potential of microRNAs as biomarkers for disease diagnosis and prognosis is propelling market growth. The rapid technological advancements in RNA sequencing and high-throughput screening techniques have also expanded the scope of microRNA applications, enabling researchers to explore novel therapeutic targets. Additionally, collaborations between academia and industry for research advancements and product development are expected to foster a conducive environment for market growth.

Key Highlights of the Market

• The microRNA market is expected to reach USD 4.2 billion by 2035.
• The CAGR for the market is projected at 12.7% from 2025 to 2035.
• The increasing prevalence of chronic diseases is a major growth driver.
• Technological advancements in diagnostic tools are set to enhance market opportunities.
• Personalized medicine is gaining traction, further driving the demand for microRNA applications.

By Product Type

Primary microRNA:

Primary microRNA (pri-miRNA) refers to the initial transcript that is synthesized in the nucleus, which later undergoes processing to form mature microRNAs. The growing demand for primary microRNAs is largely attributed to their crucial role in gene regulation and their potential to serve as biomarkers for various diseases. As the understanding of pri-miRNA's function in cellular pathways advances, research institutions and pharmaceutical companies are increasingly investing in developing diagnostic assays and therapeutics targeting these molecules. Moreover, advancements in sequencing technologies have made it easier to identify and quantify pri-miRNAs, further propelling their market growth.

Pre-microRNA:

Pre-microRNA (pre-miRNA) represents a key intermediate step in the biogenesis of microRNAs, formed when the primary transcript is processed by the Drosha enzyme. As research indicates the significant role of pre-miRNAs in post-transcriptional regulation, the market for this segment has witnessed substantial growth. The ongoing exploration and validation of pre-miRNAs as potential therapeutic targets and biomarkers for several diseases, including cancer, is driving investment and research in this area. The increasing focus on developing more efficient techniques to isolate and analyze pre-miRNAs is further anticipated to contribute to segment growth over the forecast period.

Mature microRNA:

Mature microRNAs are the functional end-products of the microRNA processing pathway and play a vital role in regulating gene expression by binding to target mRNAs. The demand for mature microRNAs is on the rise due to their crucial involvement in various biological processes, including cell proliferation, differentiation, and apoptosis. This segment is experiencing a surge in research activities aimed at understanding the mechanisms of action of mature microRNAs in disease contexts. Pharmaceutical companies are increasingly focusing on developing microRNA-based therapeutics, thereby boosting the market for mature microRNAs as key components in drug development and gene therapy initiatives.

By Application

Cancer Research:

Cancer research represents a significant application segment for microRNAs, as they are involved in tumorigenesis and progression. The exploration of specific microRNA signatures associated with different cancer types is driving the market for this application. Researchers are increasingly utilizing microRNAs as diagnostic biomarkers for early cancer detection and as therapeutic targets to enhance treatment efficacy. The focus on personalized medicine is further propelling the use of microRNAs in cancer research, as they offer potential avenues for tailored therapeutic approaches, making this one of the most lucrative segments in the microRNA market.

Infectious Diseases:

The application of microRNAs in infectious diseases is gaining traction, particularly due to their role in modulating immune responses and influencing pathogen-host interactions. Research is underway to identify specific microRNA profiles in various infectious diseases, such as viral and bacterial infections, which could pave the way for novel diagnostic tools and therapeutic strategies. The growing recognition of microRNAs as potential therapeutic agents in controlling infections is expected to foster growth in this application segment, as well as spur collaborations between academic institutions and pharmaceutical companies for the development of microRNA-based treatments against infectious diseases.

Cardiovascular Diseases:

MicroRNAs are increasingly recognized for their critical involvement in the pathophysiology of cardiovascular diseases, making this application segment highly relevant. Research has shown that specific microRNAs can serve as biomarkers for cardiac conditions, facilitating early diagnosis and intervention. Additionally, the therapeutic potential of targeting microRNAs to modulate cardiovascular pathways is an area of active investigation. The rising prevalence of cardiovascular diseases globally, coupled with advancements in microRNA research, is anticipated to drive significant growth in this segment as healthcare providers seek innovative solutions for prevention and management.

Neurological Disorders:

The application of microRNAs in neurological disorders is an evolving field that offers significant promise for research and therapeutic development. MicroRNAs play a crucial role in brain development, neurogenesis, and the regulation of neural circuits, implicating their potential involvement in disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia. Ongoing research is focused on profiling microRNAs in neurological diseases to identify potential biomarkers for diagnosis and prognostic assessment. Furthermore, the exploration of microRNA-based therapies to modulate disease progression is expected to propel growth in this application segment as the need for effective treatments in neurological disorders continues to rise.

Genetic Disorders:

MicroRNAs are increasingly being explored for their roles in genetic disorders, where dysregulation of microRNA expression can lead to pathogenesis. This application segment is witnessing growth due to the potential of microRNAs as biomarkers for genetic testing and their possible roles in gene therapy. As advances in genetic editing technologies, such as CRISPR, progress, the ability to modify microRNA expression for therapeutic purposes is becoming more feasible. The increasing focus on rare and genetic disorders, combined with the advancements in gene therapy approaches utilizing microRNA technology, is expected to drive significant growth in this application area of the microRNA market.

By Distribution Channel

Hospitals & Clinics:

The hospitals and clinics distribution channel remains a vital segment in the microRNA market, as these institutions are often the primary healthcare providers for diagnostic and therapeutic interventions. The demand for microRNA-based assays and therapies within hospitals is driven by the growing emphasis on personalized medicine and the need for accurate diagnostics in managing chronic diseases. The increasing integration of molecular diagnostics in clinical settings is further propelling this segment, as healthcare providers seek innovative solutions to enhance patient outcomes. Additionally, the collaboration between healthcare providers and research institutions is expected to facilitate the adoption of microRNA technologies in clinical practice, thus driving growth in this distribution channel.

Research Institutions:

Research institutions form a significant distribution channel in the microRNA market, as they are at the forefront of scientific discovery and innovation. The growing investments in research initiatives focused on microRNA biology are driving demand for microRNA-related products and services. Research institutions often collaborate with pharmaceutical companies and biotechnology firms to advance microRNA research, leading to the development of novel therapeutic applications and diagnostics. The increasing availability of funding for research on microRNAs, particularly in relation to chronic and genetic diseases, is expected to bolster the growth of this segment as institutions strive to explore the therapeutic potential of microRNAs.

Diagnostic Centers:

Diagnostic centers play a crucial role in the distribution of microRNA-based diagnostic assays, as they provide essential services for disease detection and monitoring. The growing trend of molecular diagnostics, including microRNA profiling, is driving the demand in this segment. As healthcare providers increasingly rely on accurate and timely diagnostics to inform treatment decisions, diagnostic centers are expanding their offerings to include microRNA-based tests. The integration of advanced technologies in diagnostics, coupled with the rising awareness of the importance of early disease detection, is anticipated to contribute significantly to the growth of this distribution channel in the microRNA market.

Pharmaceutical Companies:

Pharmaceutical companies are a prominent distribution channel in the microRNA market, as they actively engage in the development and commercialization of microRNA-based therapeutics. The growing focus on precision medicine and the increasing recognition of microRNAs as potential therapeutic targets are driving investments in this segment. Pharmaceutical companies are collaborating with research institutions to explore innovative applications of microRNAs in drug development. As the landscape of drug discovery evolves, the integration of microRNA research into pharmaceutical pipelines is expected to foster significant growth in this distribution channel, leading to the development of groundbreaking treatments for various diseases.

Online Platforms:

The rise of online platforms for the distribution of microRNA products and services is reshaping the market landscape. These platforms facilitate easy access to a wide range of microRNA-related products, including research reagents, diagnostic kits, and therapeutic agents. The convenience and efficiency of online purchasing are appealing to researchers, clinicians, and institutions, leading to increased demand through this channel. Additionally, online platforms provide valuable resources and information related to microRNA research and applications, further driving market growth. As digital transformation continues to impact various industries, the online distribution channel for microRNA products is expected to expand significantly, enhancing accessibility for users worldwide.

By Ingredient Type

miR-21:

miR-21 is one of the most studied microRNAs and is frequently associated with various types of cancer due to its role as an oncogene. The growing understanding of miR-21's involvement in tumorigenesis has led to an increased focus on this ingredient type in research and therapeutic applications. The demand for miR-21-based assays and therapies is rising, particularly in oncology, as researchers explore its potential as a biomarker for cancer diagnosis and prognosis. Additionally, miR-21 is being investigated as a therapeutic target for developing novel cancer treatments, contributing to the segment's growth in the microRNA market.

let-7:

let-7 is another significant microRNA that has gained attention for its tumor-suppressive properties. Its role in regulating cell proliferation and differentiation has made it a focal point of cancer research. The increasing recognition of let-7 as a potential therapeutic target for various cancers is driving demand in this ingredient type segment. Researchers are actively exploring let-7-based therapies and diagnostics, particularly due to its ability to regulate key oncogenes. As the understanding of let-7's function in disease contexts expands, its significance in the microRNA market is expected to grow, paving the way for innovative applications.

miR-155:

miR-155 is known for its involvement in immune response regulation and has been implicated in several diseases, including cancer and autoimmune disorders. The growing interest in miR-155 as a potential therapeutic target is driving research and development in this ingredient type. Researchers are exploring the potential of miR-155 modulation as a strategy for treating various conditions, leading to an uptick in demand for related diagnostic and therapeutic products. As the role of miR-155 in disease mechanisms becomes clearer, its market potential continues to expand, making it a key player in the microRNA landscape.

miR-34:

miR-34 is recognized for its role as a tumor suppressor and has garnered attention for its potential in cancer therapy and diagnostics. Its involvement in regulating cell cycle and apoptosis highlights its importance in cancer pathogenesis, which is driving research efforts to develop miR-34-targeting therapies. The demand for miR-34-based products is anticipated to increase as researchers continue to investigate its utility in various cancer types. The growing emphasis on precision medicine and biomarker discovery in oncology further amplifies the significance of miR-34 in the microRNA market, as it holds promise for innovative therapeutic strategies.

miR-122:

miR-122 is a liver-specific microRNA that plays a crucial role in liver function and has been implicated in liver diseases such as hepatitis and hepatocellular carcinoma. The increasing prevalence of liver-related disorders is driving demand for miR-122-based diagnostics and therapeutics. Researchers are focusing on understanding the mechanisms of miR-122 in liver pathology, which is leading to innovative applications in disease management. As the landscape for liver disease treatments evolves, the significance of miR-122 in the microRNA market is expected to grow, with potential for novel therapeutic discoveries and diagnostic tools.

By Region

North America is anticipated to hold the largest share of the microRNA market during the forecast period, primarily driven by the strong presence of key market players, advanced healthcare infrastructure, and significant investments in research and development. The region's focus on innovative healthcare solutions and personalized medicine is propelling the demand for microRNA-based technologies. Furthermore, the increasing prevalence of chronic diseases and the growing awareness of microRNA's role in diagnostics and therapeutics are expected to enhance market growth. It is projected that the North American microRNA market will grow at a CAGR of 12.5% from 2025 to 2035, further solidifying its position in the global landscape.

In Europe, the microRNA market is also experiencing significant growth, driven by rising research initiatives and collaborations among academic institutions and industry players. The European region is witnessing a surge in the number of research projects focused on microRNAs, particularly in the areas of cancer and genetic disorders. The increasing adoption of personalized medicine and molecular diagnostics is further contributing to the expansion of the microRNA market. Additionally, government-funded research programs and funding for biotechnology are expected to bolster the market, positioning Europe as a critical player in the global microRNA landscape.

Opportunities

The microRNA market presents numerous opportunities for growth, particularly in the development of novel therapeutics and diagnostic tools. The increasing recognition of microRNAs as potential biomarkers for various diseases is driving research and innovation in this area. As advancements in sequencing technologies and bioinformatics continue to evolve, the ability to profile and analyze microRNAs will enhance their application in personalized medicine. This growing emphasis on precision medicine provides a fertile ground for the development of targeted microRNA-based therapies, which could revolutionize treatment paradigms for chronic diseases, including cancer. Furthermore, the collaboration between research institutions, pharmaceutical companies, and diagnostic firms is expected to foster innovation and expedite the translation of microRNA research into clinical applications, thus creating lucrative market opportunities.

Additionally, emerging markets present significant growth opportunities for the microRNA market. As healthcare infrastructure improves and investments in research and development increase in regions such as Asia Pacific and Latin America, the demand for microRNA-based products and services is likely to rise. The growing prevalence of chronic diseases in these regions, coupled with the increasing awareness of the potential of microRNAs in diagnostics and therapeutics, will drive market penetration. Moreover, the expansion of online platforms for the distribution of microRNA products will enhance accessibility, providing an avenue for growth in underserved markets. The continuous evolution of microRNA research, combined with the global push towards personalized medicine, will undoubtedly lead to expanded opportunities in the microRNA market.

Threats

While the microRNA market is poised for growth, several threats could hinder its development. One of the significant challenges is the complexity of microRNA biology and the intricacies of gene regulation, which can lead to difficulties in translating research findings into clinically applicable solutions. The variability in microRNA expression across different tissues and disease states complicates the establishment of standardized assays and diagnostic criteria, which may limit the widespread adoption of microRNA-based products. Furthermore, the regulatory landscape for molecular diagnostics and therapeutics is becoming increasingly stringent, posing challenges for companies seeking to bring microRNA-based products to market. Navigating these regulatory hurdles can be time-consuming and costly, potentially discouraging innovation and investment in this sector.

Another threat to the microRNA market is the competition from alternative therapeutic approaches, such as small molecules and monoclonal antibodies, which may offer simpler and more established pathways for treatment. As the pharmaceutical industry continues to evolve, there is a risk that microRNA-based therapies may not receive the same level of attention and investment compared to these traditional methods. Moreover, the rising costs associated with research and development and the challenges in obtaining funding for microRNA projects could impede market growth. Therefore, industry stakeholders must remain vigilant and adapt to these challenges to harness the full potential of the microRNA market.

Competitor Outlook

• Thermo Fisher Scientific
• Qiagen
• Exiqon (a part of Qiagen)
• Life Technologies (a part of Thermo Fisher Scientific)
• Agilent Technologies
• Roche
• Takara Bio
• Integrated DNA Technologies
• Cell Signaling Technology
• New England Biolabs
• Bio-Rad Laboratories
• SABiosciences (a part of Qiagen)
• Panomics (a part of Affymetrix)
• System Biosciences
• ZyGEM Corporation

The competitive landscape of the microRNA market is characterized by a mix of established players and emerging companies, all vying for market share in this rapidly developing field. The key market participants are focused on innovation, aiming to develop novel microRNA-based products and applications to address the growing demand for personalized medicine and molecular diagnostics. Major companies, such as Thermo Fisher Scientific and Qiagen, are leveraging their extensive research and development capabilities to advance microRNA technologies and expand their product portfolios. These companies are investing significantly in research initiatives aimed at understanding microRNA biology, facilitating the development of cutting-edge diagnostics and therapeutics.

Thermo Fisher Scientific, a leader in life sciences, offers a wide range of microRNA products, including reagents, assays, and platforms for microRNA analysis. The company's commitment to innovation and its strong presence in the global market have positioned it as a key player in the microRNA landscape. Similarly, Qiagen's acquisition of Exiqon has bolstered its position in the microRNA market, allowing it to provide comprehensive solutions for microRNA research and diagnostics. Qiagen's extensive distribution network and collaboration with research institutions contribute significantly to its growth in this segment.

Other notable companies, such as Agilent Technologies, Roche, and Takara Bio, are also investing in microRNA research and product development. Agilent Technologies focuses on providing advanced microarray and sequencing technologies for microRNA analysis, catering to the needs of researchers and clinicians. Roche's commitment to advancing molecular diagnostics includes the exploration of microRNAs as potential biomarkers for various diseases. Takara Bio is actively involved in developing innovative solutions for microRNA research, leveraging its expertise in molecular biology to contribute to advancements in the field. The competitive landscape of the microRNA market continues to evolve as companies strive to capitalize on the growing opportunities within this dynamic sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Roche
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Takara Bio
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 ZyGEM Corporation
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 System Biosciences
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 New England Biolabs
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Agilent Technologies
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Bio-Rad Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Thermo Fisher Scientific
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cell Signaling Technology
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Exiqon (a part of Qiagen)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Integrated DNA Technologies
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Panomics (a part of Affymetrix)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 SABiosciences (a part of Qiagen)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Life Technologies (a part of Thermo Fisher Scientific)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 microRNA Market, By Application
    • 6.1.1 Cancer Research
    • 6.1.2 Infectious Diseases
    • 6.1.3 Cardiovascular Diseases
    • 6.1.4 Neurological Disorders
    • 6.1.5 Genetic Disorders
  • 6.2 microRNA Market, By Product Type
    • 6.2.1 Primary microRNA
    • 6.2.2 Pre-microRNA
    • 6.2.3 Mature microRNA
  • 6.3 microRNA Market, By Ingredient Type
    • 6.3.1 miR-21
    • 6.3.2 let-7
    • 6.3.3 miR-155
    • 6.3.4 miR-34
    • 6.3.5 miR-122
  • 6.4 microRNA Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Research Institutions
    • 6.4.3 Diagnostic Centers
    • 6.4.4 Pharmaceutical Companies
    • 6.4.5 Online Platforms

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 microRNA Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global microRNA market is categorized based on

By Product Type

• Primary microRNA
• Pre-microRNA
• Mature microRNA

By Application

• Cancer Research
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Genetic Disorders

By Distribution Channel

• Hospitals & Clinics
• Research Institutions
• Diagnostic Centers
• Pharmaceutical Companies
• Online Platforms

By Ingredient Type

• miR-21
• let-7
• miR-155
• miR-34
• miR-122

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Qiagen
• Exiqon (a part of Qiagen)
• Life Technologies (a part of Thermo Fisher Scientific)
• Agilent Technologies
• Roche
• Takara Bio
• Integrated DNA Technologies
• Cell Signaling Technology
• New England Biolabs
• Bio-Rad Laboratories
• SABiosciences (a part of Qiagen)
• Panomics (a part of Affymetrix)
• System Biosciences
• ZyGEM Corporation